D. Boral Capital Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $6.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 115.05% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the company. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $139.50.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX opened at $2.79 on Wednesday. GeoVax Labs has a 52 week low of $2.61 and a 52 week high of $57.00. The firm has a market cap of $3.35 million, a PE ratio of -0.08 and a beta of 3.67. The firm’s fifty day moving average is $7.09 and its 200-day moving average is $13.19.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. Sell-side analysts forecast that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the 1st quarter valued at $27,000. Hudson Bay Capital Management LP bought a new stake in GeoVax Labs in the third quarter valued at $47,000. Armistice Capital LLC acquired a new position in shares of GeoVax Labs during the third quarter valued at about $253,000. Finally, Sabby Management LLC acquired a new position in shares of GeoVax Labs during the third quarter valued at about $313,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.